Product image of Granegis (Granisetron) supplied by GNH India

Granegis

Active Ingredient:
Granisetron
Origin:
EU

Granegis (Granisetron)

Granegis is a prescription medication that contains the active ingredient granisetron, supplied as oral tablets. It belongs to the 5-HT3 receptor antagonist class and is used to prevent nausea and vomiting associated with chemotherapy and surgery. Marketed in the European Union, Granegis works by selectively blocking serotonin receptors in the central nervous system, helping to control emesis without requiring injection.

Manufacturer / TM Owner

Egis Pharmaceuticals Plc

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Granegis is indicated for the prevention and treatment of nausea and vomiting in specific clinical settings. It is commonly prescribed for patients undergoing cancer therapy or surgical procedures.

  • Prevention of chemotherapy‑induced nausea and vomiting (CINV)
  • Management of postoperative nausea and vomiting (PONV)
  • Adjunct therapy for radiation‑induced emesis
  • Use in patients who have not responded adequately to other antiemetics
  • Supportive care to improve comfort during anti‑cancer treatment

Side Effects

Granegis may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are uncommon but require medical attention.

Common

  • Headache
  • Constipation
  • Diarrhea
  • Fatigue or drowsiness
  • Dizziness
  • Flushing

Serious

  • Severe allergic reaction (rash, itching, swelling, difficulty breathing)
  • Cardiac arrhythmia or prolonged QT interval
  • Persistent severe abdominal pain
  • Signs of serotonin syndrome when combined with serotonergic agents

Precautions & Warnings

Before starting Granegis, certain health considerations should be reviewed to ensure safe use.

  • Assess cardiac history, especially QT prolongation risk
  • Review concomitant medications that affect heart rhythm
  • Use cautiously in patients with hepatic impairment
  • Monitor for signs of allergic reactions during initial dosing
  • Discuss pregnancy and breastfeeding status with a healthcare professional
  • Adjust dose in elderly patients if renal function is reduced

Avoid Interactions

Granegis can interact with other drugs, influencing its effectiveness or safety profile.

Avoid

  • Other 5‑HT3 antagonists or drugs that significantly prolong QT interval (e.g., certain antiarrhythmics, antipsychotics)
  • Strong CYP3A4 inhibitors that may increase granisetron levels

Use with caution

  • Serotonergic agents such as SSRIs, SNRIs, or tramadol (risk of serotonin syndrome)
  • Medications that also cause constipation (may exacerbate gastrointestinal effects)
  • Drugs metabolized by the same hepatic pathways (monitor for altered plasma concentrations)

Frequently Asked Questions

Granegis contains granisetron, which selectively blocks 5‑HT3 receptors in the central nervous system, preventing serotonin‑mediated signals that trigger nausea and vomiting.

It is prescribed for adults receiving chemotherapy or undergoing surgery who need prevention of nausea and vomiting, especially when other antiemetics are insufficient.

Granegis is taken orally, usually as a tablet, according to the dosing schedule provided by a healthcare professional.

The pregnancy safety category for granisetron is not definitively established; pregnant individuals should discuss potential risks and benefits with their doctor before use.

Common side effects include headache, constipation, diarrhea, fatigue, dizziness, and flushing, most of which are mild and temporary.

Seek immediate medical care if you experience signs of a severe allergic reaction, persistent abdominal pain, irregular heartbeats, or symptoms of serotonin syndrome such as agitation, rapid heart rate, or high fever.

Granegis may interact with serotonergic antidepressants (SSRIs, SNRIs) and increase the risk of serotonin syndrome; use together only under medical supervision.

Patients with significant hepatic impairment should be monitored closely, and dose adjustments may be considered based on clinical response and tolerability.

Granegis can be combined with antiemetics of different classes, but combining it with other 5‑HT3 antagonists or drugs that prolong QT interval should be avoided.

The duration of effect varies with the dose and individual metabolism, but granisetron generally provides relief for several hours after administration.

Avoid medications that significantly prolong the QT interval and strong CYP3A4 inhibitors unless directed by a healthcare provider.

No, Granegis is a prescription‑only medication and must be obtained through a licensed healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Granisetron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT